Enhanced Liver Fibrosis Test, FIB ‐4 and FibroScan : Real‐World Prognostic Accuracy for MASLD in a Biopsy‐Controlled Cohort
Liver International · 2026-08 · 46 (8)
DOI: 10.1111/liv.70774 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Liver International, online erschienen am 02.07.2026. Verfasst von Antonio Liguori und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgery Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Elasticity Imaging Techniques, Fatty Liver, Liver, Liver Cirrhosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Siemens Healthineers, Fondazione Roma.
Abstract (Originalsprache)
Background and Aims Liver fibrosis is a major determinant of liver‐related events (LREs) in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). Effective stratification based on fibrosis severity is essential for accurate prognosis. The Enhanced Liver Fibrosis (ELF) test, a non‐invasive test measuring direct fibrosis markers, offers a potential alternative to traditional methods like FIB‐4, liver stiffness measurement (LSM) and liver biopsy. This study aims to evaluate the prognostic value of the ELF test in comparison with these established methods.
Methods
We retrospectively analysed 289 MASLD patients (30.4% female, median age 49 years [IQR 39–58], 28% with type 2 diabetes) from the PROMETEO cohort (NCT04371042). We excluded patients with prior or current evidence of decompensated cirrhosis. At baseline, patients underwent liver biopsy, FIB‐4, ELF and LSM assessments. The primary outcome was development of Liver Related Events (LRE), a composite of liver‐related death, hepatocellular carcinoma, liver transplantation, ascites, encephalopathy or variceal bleeding.
Results
Over a median follow‐up of 64 months [IQR 39–81], 41 patients (14.2%) experienced LREs. Event rates increased markedly across ELF categories (1% for ELF < 9.8, 27.8% for ELF ≥ 9.8 to < 11.3 and 72.7% for ELF ≥ 11.3). ELF demonstrated discriminative performance comparable to histological fibrosis stage and LSM, with the highest overall AUC among evaluated tests. In adjusted Cox models, higher ELF categories remained strongly associated with LRE risk, although confidence intervals were wide due to the limited number of events.
Conclusions
In this biopsy‐proven MASLD cohort, ELF provided prognostic stratification for liver‐related events comparable to liver histology and LSM. Given the limited number of outcome events, these findings support the non‐inferiority of ELF rather than definitive superiority. Larger prospective studies are needed to confirm these results and refine risk prediction strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgery Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
- Department of Laboratory and Hematology Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Women, Children and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Computational Biology and Bioinformatics Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
ORCID-Profile: Antonio Liguori, Francesca D'Ambrosio, Giulia Angelini, Consuelo Cefalo, Maria Cristina Giustiniani, Giuseppe Marrone, Marco Biolato, Gianludovico Rapaccini, Maurizio Pompili, Antonio Grieco, Tommaso Mazza, Andrea Urbani, Maurizio Sanguinetti, Antonio Gasbarrini, Luca Miele
Förderung
- Siemens Healthineers
- Fondazione Roma
Zitieren
APA
Liguori, A., D'Ambrosio, F., Angelini, G., Cefalo, C., Galletti, S., Cardinali, S., Giustiniani, M. C., Marrone, G., Biolato, M., Rapaccini, G., Pompili, M., Grieco, A., Mazza, T., Urbani, A., Sanguinetti, M., Gasbarrini, A., FPG‐UCSC PROMETEO‐ELF substudy Research Group, & Miele, L. (2026). Enhanced Liver Fibrosis Test, FIB ‐4 and FibroScan : Real‐World Prognostic Accuracy for MASLD in a Biopsy‐Controlled Cohort. Liver International, 46(8). https://doi.org/10.1111/liv.70774
Vancouver
Liguori A, D'Ambrosio F, Angelini G, Cefalo C, Galletti S, Cardinali S, et al. Enhanced Liver Fibrosis Test, FIB ‐4 and FibroScan : Real‐World Prognostic Accuracy for MASLD in a Biopsy‐Controlled Cohort. Liver International. 2026;46(8). doi:10.1111/liv.70774
BibTeX
@article{Liguori2026,
author = {Liguori, Antonio and D'Ambrosio, Francesca and Angelini, Giulia and Cefalo, Consuelo and Galletti, Simone and Cardinali, Sara and Giustiniani, Maria Cristina and Marrone, Giuseppe and Biolato, Marco and Rapaccini, Gianludovico and Pompili, Maurizio and Grieco, Antonio and Mazza, Tommaso and Urbani, Andrea and Sanguinetti, Maurizio and Gasbarrini, Antonio and FPG‐UCSC PROMETEO‐ELF substudy Research Group, FPG‐UCSC PROMETEO‐ELF substudy Research Group and Miele, Luca},
title = {Enhanced Liver Fibrosis Test, FIB ‐4 and FibroScan : Real‐World Prognostic Accuracy for MASLD in a Biopsy‐Controlled Cohort},
journal = {Liver International},
year = {2026},
volume = {46},
number = {8},
doi = {10.1111/liv.70774}
}
EUVIMED